相似文献
1
2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?
ACS Pharmacol Transl Sci. 2024 Feb 20;7(3):899-903. doi: 10.1021/acsptsci.4c00031. eCollection 2024 Mar 8.
2
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase .
J Med Chem. 2023 Oct 12;66(19):13821-13837. doi: 10.1021/acs.jmedchem.3c01345. Epub 2023 Oct 2.
3
Development of the first non-hydroxamate selective HDAC6 degraders.
Chem Commun (Camb). 2022 Oct 4;58(79):11087-11090. doi: 10.1039/d2cc03712b.
4
Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.
Int J Mol Sci. 2024 May 28;25(11):5885. doi: 10.3390/ijms25115885.
5
Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
J Biol Chem. 2023 Jan;299(1):102800. doi: 10.1016/j.jbc.2022.102800. Epub 2022 Dec 15.
6
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
J Med Chem. 2023 Oct 26;66(20):14188-14207. doi: 10.1021/acs.jmedchem.3c01269. Epub 2023 Oct 5.
7
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Expert Opin Ther Pat. 2018 Aug;28(8):647-651. doi: 10.1080/13543776.2018.1508451. Epub 2018 Aug 7.
8
Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
Recent Pat Anticancer Drug Discov. 2020;15(1):32-48. doi: 10.2174/1574892815666200217125419.
9
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).
ACS Chem Biol. 2023 Jul 21;18(7):1594-1610. doi: 10.1021/acschembio.3c00212. Epub 2023 Jul 1.
10
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Eur J Med Chem. 2021 Jan 1;209:112887. doi: 10.1016/j.ejmech.2020.112887. Epub 2020 Sep 29.
本文引用的文献
1
Interactions of Histone Deacetylase 6 with DNA Damage Repair Factors Strengthen its Utility as a Combination Drug Target in High-Grade Serous Ovarian Cancer.
ACS Pharmacol Transl Sci. 2023 Nov 16;6(12):1924-1933. doi: 10.1021/acsptsci.3c00215. eCollection 2023 Dec 8.
2
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
J Med Chem. 2023 Oct 26;66(20):14188-14207. doi: 10.1021/acs.jmedchem.3c01269. Epub 2023 Oct 5.
3
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase .
J Med Chem. 2023 Oct 12;66(19):13821-13837. doi: 10.1021/acs.jmedchem.3c01345. Epub 2023 Oct 2.
4
The Importance of the "Time Factor" for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors.
Biology (Basel). 2023 Jul 26;12(8):1049. doi: 10.3390/biology12081049.
5
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).
ACS Chem Biol. 2023 Jul 21;18(7):1594-1610. doi: 10.1021/acschembio.3c00212. Epub 2023 Jul 1.
6
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
Int J Mol Sci. 2023 Mar 1;24(5):4720. doi: 10.3390/ijms24054720.
7
Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
J Biol Chem. 2023 Jan;299(1):102800. doi: 10.1016/j.jbc.2022.102800. Epub 2022 Dec 15.
8
Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge.
ACS Pharmacol Transl Sci. 2022 Oct 10;5(11):1128-1141. doi: 10.1021/acsptsci.2c00119. eCollection 2022 Nov 11.
9
Development of the first non-hydroxamate selective HDAC6 degraders.
Chem Commun (Camb). 2022 Oct 4;58(79):11087-11090. doi: 10.1039/d2cc03712b.
10
Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs.
ACS Pharmacol Transl Sci. 2022 Jan 27;5(2):138-140. doi: 10.1021/acsptsci.2c00004. eCollection 2022 Feb 11.
Zotero 插件